Table 2 Baseline data sheet
Characteristic | Low expression of COL5A2 | High expression of COL5A2 | p |
|---|---|---|---|
n | 187 | 188 | Â |
T stage, n (%) | Â | Â | 0.009 |
 T1 | 16 (4.4%) | 3 (0.8%) |  |
 T2 | 44 (12%) | 36 (9.8%) |  |
 T3 | 84 (22.9%) | 84 (22.9%) |  |
 T4 | 43 (11.7%) | 57 (15.5%) |  |
N stage, n (%) | Â | Â | 0.772 |
 N0 | 54 (15.1%) | 57 (16%) |  |
 N1 | 53 (14.8%) | 44 (12.3%) |  |
 N2 | 38 (10.6%) | 37 (10.4%) |  |
 N3 | 35 (9.8%) | 39 (10.9%) |  |
M stage, n (%) | Â | Â | 0.965 |
 M0 | 167 (47%) | 163 (45.9%) |  |
 M1 | 12 (3.4%) | 13 (3.7%) |  |
Pathologic stage, n (%) | Â | Â | 0.342 |
 Stage I | 33 (9.4%) | 20 (5.7%) |  |
 Stage II | 53 (15.1%) | 58 (16.5%) |  |
 Stage III | 74 (21%) | 76 (21.6%) |  |
Stage IV | 19 (5.4%) | 19 (5.4%) | Â |
Primary therapy outcome, n (%) | Â | Â | 0.860 |
 PD | 35 (11%) | 30 (9.5%) |  |
 SD | 7 (2.2%) | 10 (3.2%) |  |
 PR | 2 (0.6%) | 2 (0.6%) |  |
 CR | 118 (37.2%) | 113 (35.6%) |  |
Gender, n (%) | Â | Â | 0.313 |
 Female | 72 (19.2%) | 62 (16.5%) |  |
 Male | 115 (30.7%) | 126 (33.6%) |  |
Race, n (%) | Â | Â | 0.083 |
 Asian | 37 (11.5%) | 37 (11.5%) |  |
 Black or African American | 9 (2.8%) | 2 (0.6%) |  |
 White | 113 (35%) | 125 (38.7%) |  |
Age, n (%) | Â | Â | 0.422 |
  < =65 | 87 (23.5%) | 77 (20.8%) |  |
  > 65 | 100 (27%) | 107 (28.8%) |  |
Histological type, n (%) | Â | Â | 0.056 |
 Diffuse Type | 27 (7.2%) | 36 (9.6%) |  |
 Mucinous Type | 6 (1.6%) | 13 (3.5%) |  |
 Not Otherwise Specified | 100 (26.7%) | 107 (28.6%) |  |
 Papillary Type | 3 (0.8%) | 2 (0.5%) |  |
 Signet Ring Type | 6 (1.6%) | 5 (1.3%) |  |
 Tubular Type | 45 (12%) | 24 (6.4%) |  |
Residual tumor, n (%) | Â | Â | 0.886 |
 R0 | 157 (47.7%) | 141 (42.9%) |  |
 R1 | 7 (2.1%) | 8 (2.4%) |  |
 R2 | 8 (2.4%) | 8 (2.4%) |  |
Histologic grade, n (%) | Â | Â | 0.152 |
 G1 | 5 (1.4%) | 5 (1.4%) |  |
 G2 | 77 (21%) | 60 (16.4%) |  |
 G3 | 100 (27.3%) | 119 (32.5%) |  |
Reflux history, n (%) | Â | Â | 0.286 |
 No | 93 (43.5%) | 82 (38.3%) |  |
 Yes | 25 (11.7%) | 14 (6.5%) |  |
Antireflux treatment, n (%) | Â | Â | 0.321 |
 No | 69 (38.5%) | 73 (40.8%) |  |
 Yes | 22 (12.3%) | 15 (8.4%) |  |
H pylori infection, n (%) | Â | Â | 0.959 |
 No | 86 (52.8%) | 59 (36.2%) |  |
 Yes | 10 (6.1%) | 8 (4.9%) |  |
Barretts esophagus, n (%) | Â | Â | 0.790 |
 No | 115 (55.3%) | 78 (37.5%) |  |
 Yes | 10 (4.8%) | 5 (2.4%) |  |
OS event, n (%) | Â | Â | 0.022 |
 Alive | 125 (33.3%) | 103 (27.5%) |  |
 Dead | 62 (16.5%) | 85 (22.7%) |  |
DSS event, n (%) | Â | Â | 0.038 |
 Alive | 142 (40.1%) | 121 (34.2%) |  |
 Dead | 37 (10.5%) | 54 (15.3%) |  |
PFI event, n (%) | Â | Â | 0.164 |
 Alive | 132 (35.2%) | 119 (31.7%) |  |
 Dead | 55 (14.7%) | 69 (18.4%) |  |